> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Wave Will Say This Quarter Whether Obesity Data Comes At Three Months Or Six
- URL: https://www.bullished.co/wave-will-say-this-quarter-whether-obesity-data-comes-at-three-months-or-six-7de51565/
- Published: 2026-10-27T14:01:55.000Z
- Updated: 2026-10-29T18:03:49.000Z
- Description: CEO Paul Bolno says the three-month look at WVE-007 would show body composition, not weight loss, and an update on timing is coming.
- Author: Matteo Parrino
- Tags: Earnings, WVE, Industry: Healthcare

[Wave Life Sciences](https://www.bullished.co/tag/wve/), which develops RNA medicines, may begin delivering Phase 2a data on its obesity drug WVE-007 this year, CEO Paul Bolno said on the company's third-quarter earnings call on Tuesday. Revenue came in at [$13.2 million](https://www.globenewswire.com/news-release/2026/10/27/3388867/0/en/wave-life-sciences-reports-third-quarter-2026-financial-results-and-provides-business-update.html?ref=bullished.co), against $7.6 million a year earlier.

## Three months or six

Wave is analyzing whether to cut the Phase 2a data at three months or at six months, Bolno said, answering a Leerink Partners analyst. He called three months a body-composition time point, where early fat loss comes with muscle and lean-mass gains, and not the point to judge weight loss. Six months is when weight loss can be assessed.

More on timing and updates will come this quarter, Bolno said.

A William Blair analyst asked whether Wave still feels confident of reaching 5% weight loss at 12 months. Bolno said the company's modeling points to a path to that regulatory bar, helped by patients with more baseline fat to lose.

## A heavier trial population

Chief Medical Officer Chris Wright said participants dosed so far have baseline adiposity [substantially higher than in the Phase 1 portion](https://finance.yahoo.com/healthcare/articles/wave-life-sciences-reports-third-113000429.html?ref=bullished.co), in line with Phase 2 and 3 obesity trials. The placebo-controlled trial enrolls people with BMI of 35 to 50 and comorbidities, in four cohorts of up to 40 participants each, at 240 and 400 milligrams. Participants get two doses, on day one and day 85, and are followed for up to 12 months.

Bolno pitched WVE-007 as driving fat loss without muscle loss. He said muscle can account for upwards of 40% of weight lost on current therapies.

## Weight regain and the next steps

Wave remains on track to start a [post-incretin maintenance trial](https://finance.yahoo.com/healthcare/articles/wave-life-sciences-reports-third-113000429.html?ref=bullished.co) in the fourth quarter, aimed at preventing weight regain. Bolno said upwards of 70% of lost weight is regained after GLP-1 therapy stops, driven by fat rather than muscle. The company also expects 600 milligram Phase 1 data this quarter.

On the financials, research and development spending rose to $53.8 million from $45.9 million. General and administrative expenses were $25.4 million, against $18.1 million. Wave expects a [$12 million milestone](https://seekingalpha.com/news/4657784-wave-life-sciences-gaap-eps-of--030-beats-by-003-revenue-of-1316m-beats-by-877m?ref=bullished.co) payment from GSK in the fourth quarter after GSK picked an siRNA development candidate.

Wave holds its annual Research Day next week.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [Wave Life Sciences GAAP EPS of -$0.30 beats by $0.03, revenue of $13.16M beats by $8.77M (WVE:NASDAQ) | Seeking Alpha](https://seekingalpha.com/news/4657784-wave-life-sciences-gaap-eps-of--030-beats-by-003-revenue-of-1316m-beats-by-877m?ref=bullished.co) — seekingalpha.com
- [Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update](https://finance.yahoo.com/healthcare/articles/wave-life-sciences-reports-third-113000429.html?ref=bullished.co) — Yahoo Finance
- [8-K](https://www.sec.gov/Archives/edgar/data/1631574/000119312526432690/d120442d8k.htm?ref=bullished.co) — sec.gov
- [Wave Life Sciences (WVE) Reports Q3 Loss, Tops Revenue Estimates](https://finance.yahoo.com/healthcare/articles/wave-life-sciences-wve-reports-114003493.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Wave Life Sciences Reports Third Quarter 2026 Financial](https://www.globenewswire.com/news-release/2026/10/27/3388867/0/en/wave-life-sciences-reports-third-quarter-2026-financial-results-and-provides-business-update.html?ref=bullished.co) — globenewswire.com

### More on Wave Life Sciences

- [BlackRock Reports 6.8% Passive Stake In Wave Life Sciences, A Stock Down About 81% This Year](https://www.bullished.co/blackrock-reports-6-8-passive-stake-in-wave-life-sciences-a-stock-down-about-81-this-year-7e445b6c/)
- [Wave Plans One Two-Year Trial To Seek Both Fast-Track And Full Approval Of Its AATD Drug](https://www.bullished.co/wave-plans-one-two-year-trial-to-seek-both-fast-track-and-full-approval-of-its-aatd-drug-65e2b6d7/)
- [Wave Life Sciences Moved $233 Million Into Securities As A GSK Milestone Lifted Revenue](https://www.bullished.co/wave-life-sciences-moved-233-million-into-securities-as-a-gsk-milestone-lifted-revenue-cb15473c/)

[All Wave Life Sciences (WVE) coverage →](https://www.bullished.co/tag/wve/)